Noble Life Science Partners
    Nathan Cali

    Communiqués de Presse

     

    Veuillez noter : La langue de travail principale de Aequus Pharmaceuticals Inc., est l'anglais. Les investisseurs sont invités à visiter le site Web anglais pour lire les communiqués de presse en cliquant ici.

    Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch

    Aequus Announces Change to Proposed $300,000 Equity Financing

    Aequus Announces Proposed $300,000 Equity Financing

    Aequus announces the issuance of stock options

    Aequus Provides Third Quarter 2017 Operational Highlights

    Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Provides Second Quarter 2017 Operational Highlights

    Aequus and Ehave Collaborate on Bioinformatics Platform for Management of Clinical Trials

    Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

    Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

    Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch

    Santen and Aequus Enter Into a Commercial Collaboration in Canada

    Aequus Approves Advance Notice Policy

    Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics

    Aequus Provides First Quarter 2017 Financial Highlights